Effectiveness of Haemophilus influenzae type b conjugate vaccine introduction into routine childhood immunization in Kenya

JAMA

Volumn 296, Issue 6, 2006, Pages 671-678

  Cowgill, Karen D ^a   Ndiritu, Moses ^c   Nyiro, Joyce ^c   Slack, Mary P E ^e   Chiphatsi, Salome ^d   Ismail, Amina ^f   Kamau, Tatu ^f   Mwangi, Isaiah ^c   English, Mike ^c,g   Newton, Charles R J C ^c,i   Feikin, Daniel R ^b   Scott, J Anthony G ^c,h  

^a NATL CENTER FOR INFECTIOUS DISEASES   (United States)

^b NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^c KEMRI WELLCOME TRUST RESEARCH PROGRAMME   (Kenya)

^d Kilifi District Hospital   (Kenya)

^e PUBLIC HEALTH ENGLAND   (United Kingdom)

^f MINISTRY OF HEALTH   (Kenya)

^g UNIVERSITY OF OXFORD   (United Kingdom)

^h UNIVERSITY OF OXFORD   (United Kingdom)

ⁱ UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; HAEMOPHILUS INFLUENZAE TYPE B VACCINE; HEPATITIS B VACCINE;

ARTICLE; BACTERIUM CULTURE; DRUG EFFICACY; FATALITY; FEMALE; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; INFANT; INFLUENZA; INFLUENZA VACCINATION; KENYA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRESCHOOL CHILD; PREVENTIVE HEALTH SERVICE; PRIORITY JOURNAL;

EID: 33746903584     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.296.6.671     Document Type: Article

References (31)

1. Peltola H. Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates. Clin Microbiol Rev. 2000;13:302-317.
2. Berkley JA, Lowe BS, Mwangi I, et al. Bacteremia among children admitted to a rural hospital in Kenya. N Engl J Med. 2005;352:39-47.
3. Eskola J, Peltola H, Takala AK, et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med. 1987;317:717-722.
4. Black SB, Shinefield HR, Fireman B, Hiatt R, Polen M, Vittinghoff E; Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. Pediatr Infect Dis J. 1991;10:97-104.
5. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet. 1992;340:592-594.
6. Bisgard KM, Kao A, Leake J, Strebel PM, Perkins BA, Wharton M. Haemophilus influenzae invasive disease in the United States, 1994-1995: near disappearance of a vaccine-preventable childhood disease. Emerg Infect Dis. 1998;4:229-237.
7. Mulholland K, Hilton S, Adegbola R, et al. Randomised trial of Haemophilus influenzae type-b tetanus protein conjugate vaccine [corrected] for prevention of pneumonia and meningitis in Gambian infants. Lancet. 1997;349:1191-1197.
8. Mwangi I, Berkley J, Lowe B, Peshu N, Marsh K, Newton CRJ. Acute bacterial meningitis in children admitted to a rural Kenyan hospital: increasing antibiotic resistance and outcome. Pediatr Infect Dis J. 2002;21:1042-1048.
9. Berkley JA, Versteeg AC, Mwangi I, Lowe BS, Newton CRJ. Indicators of acute bacterial meningitis in children at a rural Kenyan district hospital. Pediatrics. 2004;114:e713-e719.
10. Falla TJ, Crook DW, Brophy LN, Maskell D, Kroll JS, Moxon ER. PCR for capsular typing of Haemophilus influenzae. J Clin Microbiol. 1994;32:2382-2386.
11. Newell C. Methods and Models in Demography. London, England: Belhaven Press; 1988:180-184.
12. Berkley JA, Mwangi I, Ngetsa CJ, et al. Diagnosis of acute bacterial meningitis in children at a district hospital in sub-Saharan Africa. Lancet. 2001;357:1753-1757.
13. Ndiritu M, Cowgill KD, Ismail A, et al. Immunization coverage and risk factors for failure to immunize within the Expanded Programme on Immunization in Kenya after introduction of new Haemophilus influenzae type b and hepatitis B virus antigens. BMC Public Health. 2006;6:132.
14. Santosham M, Wolff M, Reid R, et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med. 1991;324:1767-1772.
15. Lagos R, Valenzuela MT, Levine OS, et al. Economisation of vaccination against Haemophilus influenzae type b: a randomised trial of immunogenicity of fractional-dose and two-dose regimens. Lancet. 1998;351:1472-1476.
16. Adegbola RA, Secka O, Lahai G, et al. Elimination of Haemophilus influenzae type b (Hib) disease from The Gambia after the introduction of routine immunisation with a Hib conjugate vaccine: a prospective study. Lancet. 2005;366:144-150.
17. Central Bureau of Statistics (CBS) [Kenya], Ministry of Health (MOH) [Kenya], andORCMacro. Kenya Demographic and Health Survey 2003. Calverton, Md: Central Bureau of Statistics, Ministry of Health, ORC Macro; 2005.
18. Hussey G, Hitchcock J, Schaaf H, et al. Epidemiology of invasive Haemophilus influenzae infections in Cape Town, South Africa. Ann Trop Paediatr. 1994;14:97-103.
19. Sow SO, Diallo S, Campbell JD, et al. Burden of invasive disease caused by Haemophilus influenzae type b in Bamako, Mali: impetus for routine infant immunization with conjugate vaccine. Pediatr Infect Dis J. 2005;24:533-537.
20. Campagne G, Garba A, Schuchat A, et al. Response to conjugate Haemophilus influenzae B vaccine among infants in Niamey, Niger. Am J Trop Med Hyg. 1998;59:837-842.
21. Bijlmer HA, van Alphen L, Greenwood BM, et al. The epidemiology of Haemophilus influenzae meningitis in children under five years of age in The Gambia, West Africa. J Infect Dis. 1990;161:1210-1215.
22. Adegbola RA, Usen SO, Weber M, et al. Haemophilus influenzae type b meningitis in The Gambia after introduction of a conjugate vaccine. Lancet. 1999;354:1091-1092.
23. Lagos R, Horwitz I, Toro J, et al. Large scale, postlicensure, selective vaccination of Chilean infants with PRP-T conjugate vaccine: practicality and effectiveness in preventing invasive Haemophilus influenzae type b infections. Pediatr Infect Dis J. 1996;15:216-222.
24. Murphy TV, White KE, Pastor P, et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA. 1993;269:246-248.
25. Urwin G, Yuan MF, Feldman RA. Prospective study of bacterial meningitis in North East Thames region, 1991-3, during introduction of Haemophilus influenzae vaccine. BMJ. 1994;309:1412-1414.
26. US Census Bureau, Population Division, International Programs Center. International data base. http://www.census.gov/ipc/www/idbnew.html. Accessed February 28, 2006.
27. Snow RW, Schellenberg JR, Forster D, Mung'ala VO, Marsh K. Factors influencing admission to hospital during terminal childhood illnesses in Kenya. Int J Epidemiol. 1994;23:1013-1019.
28. Mulholland K, Levine O, Nohynek H, Greenwood BM. Evaluation of vaccines for the prevention of pneumonia in children in developing countries. Epidemiol Rev. 1999;21:43-55.
29. Madhi SA, Kuwanda L, Saarinen L, et al. Immunogenicity and effectiveness of Haemophilus influenzae type b conjugate vaccine in HIV infected and uninfected African children. Vaccine. 2005;23:5517-5525.
30. Barbour ML, Mayon-White RT, Coles C, Crook DW, Moxon ER. The impact of conjugate vaccine on carriage of Haemophilus influenzae type b. J Infect Dis. 1995;171:93-98.
31. Moulton LH, Chung S, Croll J, Reid R, Weatherholtz RC, Santosham M. Estimation of the indirect effect of Haemophilus influenzae type b conjugate vaccine in an American Indian population. Int J Epidemiol. 2000;29:753-756.